BioStock: PHI aims for US listing

July 11, 2024
Language flag

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

PHI-at-Aktieportfoljen-Live

PHI presents at Aktieportföljen Live

Watch CEO Anders Månsson present the Company and its future plans at Aktieportföljen Live.
PHI-at-analyst-group-interview-anders-mansson

Analyst Group Intervju med PHIs VD Anders Månsson

Analyst Group intervjuar Anders Månsson, VD för Phase Holographic Imaging, i samband med bolagets företrädesemission år 2024.
Biostock-Phase-Holographic-Imaging-1280px-Anders-Goran

BioStock: Studio interview with Anders Månsson and Goran Dubravčić

Recently, PHI welcomed Anders Månsson as its new CEO. In a video interview, Månsson and Chairman of the Board Goran Dubravčić discuss the company’s future strategy and the ongoing rights issue.
phi-right-moment-to-capitalize-on-regenerative-medicine-momentum

BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”

Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.
12345…10

Latest News

The HoloMonitor HoloLids are specially designed to eliminate image disturbances, caused by surface vibrations and condensation inside the cell culture vessel.

Interim Report 4 2024/25

This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
A red pin on a blue map.

Phase Holographic: Proposal to amend the Altium Distribution Agreement

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) announces that the Board of Directors has decided to call for an Extraordinary General Meeting to approve a proposed amendment of the distribution agreement with Altium SA (“Altium”), the Company’s global distributor and main shareholder.
A magnifying glass on a paper with blue charts.

Phase Holographic: Sales summary and profit warning for the fiscal year 2024/2025

Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today provides an update on the Company’s sales for the fiscal year 2024/2025. Based on the most recent developments and actual order volumes, total sales for the fiscal year are now expected to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.
See All News